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Abstract 
Alzheimer’s disease (AD) is a neurodegenerative disorder associated with an excessive accumulation of 
amyloid-beta peptide (Aβ). Based on the multifactorial nature of AD, preparation of multi-target-directed 
ligands presents a viable option to address more pathological events at one time. A novel class of 
asymmetrical disubstituted indolyl thioureas have been designed and synthesized to interact with 
monoamine oxidase (MAO) and/or amyloid-binding alcohol dehydrogenase (ABAD). The design combines 
the features of known MAO inhibitors scaffolds (e.g. rasagiline or ladostigil) and a frentizole moiety with 
potential to interact with ABAD. Evaluation against MAO identified several compounds that inhibited in the 
low to moderate micromolar range. The most promising compound (19) inhibited human MAO-A and MAO-
B with IC50 values of 6.34 μM and 0.30 μM, respectively. ABAD activity evaluation did not show any highly 
potent compound, but the compound series allowed identification of structural features to assist the future 
development of ABAD inhibitors. Finally, several of the compounds were found to be potent inhibitors of 
horseradish peroxidase (HRP), preventing the use of the Amplex™ Red assay to detect hydrogen peroxide 
produced by MAO, highlighting the need for serious precautions when using an enzyme-coupled assay. 
 
  
2 
 
Keywords 
Alzheimer's disease (AD); monoamine oxidase (MAO); amyloid-beta peptide (Aβ); mitochondrial 
amyloid-binding alcohol dehydrogenase (ABAD); 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10); 
horseradish peroxidase (HRP). 
 
1. Introduction 
Alzheimer’s disease (AD) is the most common cause of senile dementia and is characterized by a 
progressive impairment of cognitive functions including memory, language and motor skills.1,2 Though the 
aetiology of AD still remains unclear, there are several established factors contributing to the progress of 
AD including e.g. alteration in neurotransmitter systems, deposition of amyloid beta peptide (Aβ), tau-
protein hyperphoshorylation with tangle formation, oxidative stress and mitochondrial dysfunction.3,4 
Most of the currently marketed drugs (namely donepezil, rivastigmine, galanthamine) prevent the 
degradation of acetylcholine via the inhibition of acetylcholinesterase to sustain sufficient levels in the face 
of the decreased numbers of cholinergic neurons in AD.5 This approach is only effective for symptomatic 
treatment of mild and moderate cognitive decline and does not provide prevention of disease progression.6 
Alongside the well-established dysregulation of cholinergic system, the impairment of other 
neurotransmitter systems (e.g. dopaminergic or serotonergic) is also present in the brain of AD patients, 
causing behavioural syndromes in AD patients.7 Thus, monoamine oxidases (MAO), enzymes responsible 
for the metabolism of monoamine neurotransmitters, were suggested as possible targets for AD 
treatment.8 MAO occurs in two isoforms (MAO-A and MAO-B) with different substrate and inhibitor 
specificities.8–10 Alterations of both MAO-A and MAO-B activities (elevated enzyme levels or changes in 
expression in various brain regions) were reported in AD patient brains.11–13 While elevated levels of MAO-B 
are well-described, changes in MAO-A activity are rather more complex and unclear.14 In the periphery, 
inhibition of MAO-A can contribute to potential side effects, in particular to tyramine-induced hypertension 
(also referred as the “cheese effect”). It is induced by dietary amines after the irreversible inhibition of 
intestinal MAO-A where the inhibitor is covalently bound to the enzyme (via hydrazine or propargyl-amino 
moiety).8 Furthermore, elevated levels of the MAO isoforms can also generate toxic metabolites (e.g. 
aldehydes or hydrogen peroxide),15 which consequently promote already ongoing oxidative stress in AD.16 
Taken together, targeting both MAO-A and MAO-B could potentially contribute to therapeutic effects in AD 
treatment. 
Besides the neurotransmission anomalies, one of the most widely accepted AD hypothesis focuses on 
the pathological production of Aβ leading to formation of insoluble extracellular Aβ plaques.17,18 Intra-
mitochondrial Aβ deposition has been associated with mitochondrial dysfunction and impaired synaptic 
trafficking resulting in neuronal damage.19,20 Thus, Aβ interactions with mitochondrial proteins may become 
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therapeutic targets for cellular protection in AD.21 Several mitochondrial proteins have been shown to 
interact directly with Aβ, possibly influencing mitochondrial metabolism.22 The amyloid-binding alcohol 
dehydrogenase (ABAD) enzyme, also known as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), is 
one such Aβ binding protein.23 The Aβ-ABAD interaction promotes the enzyme to undergo functional 
changes, resulting in altered enzymatic activity, elevated levels of toxic metabolites, enhanced oxidative 
stress and mitochondrial and synaptic dysfunction.24–26 Studies using an ABAD decoy peptide consisting of 
the ABAD amino acid residues responsible for interaction with Aβ, have been shown to disrupt the 
interaction between ABAD and Aβ, reducing Aβ-induced mitochondrial and neuronal toxicity and improving 
learning and memory in AD mice models.25,27 Further, the direct inhibition of the ABAD enzyme has been 
shown to have neuroprotective effects in terms of reducing cell stress via decreased generation of reactive 
oxygen species, improved mitochondrial respiration, and stabilization of estradiol levels.28,29 Thus both the 
direct inhibition of ABAD enzyme and the disruption of the Aβ-ABAD interaction present possible 
approaches for AD treatment.29 
Due to the multifactorial nature of AD aetiology, the question whether a single-target-directed drug 
could yield therapeutic effect in AD treatment has led scientists to focus still more on the emerging multi-
target-directed ligand (MTDL) approach.30 Simultaneous modulation of several pathological events of the 
ongoing disease may then contribute to therapeutic effect of progressing AD.31 The MTDL approach has 
been employed by many research groups32–35 and has shown success, for example in the case of the 
compound ladostigil36 which has reached clinical trials.37 Exploiting the advantage of conjunctive approach, 
we designed a series of compounds combining known scaffolds of MAO and ABAD inhibitors to introduce 
MAO inhibitory activity into frentizole moiety and explore structural inhibitory features of both MAO and 
ABAD scaffolds. Xie et al. observed that the FDA approved drug, frentizole (Fig. 1: A), acted as a weak 
inhibitor of the Aβ-ABAD interaction (IC50 = 200 μM) and described a novel class of frentizole-based 
benzothiazolyl (thio)ureas acting as inhibitors of the Aβ-ABAD interaction.38 Relatively minimal 
modifications of the distal phenyl ring substitution also allowed phosphonate analogues of the same 
scaffold to act as direct ABAD inhibitors, yielding two compounds that inhibited ABAD with IC50 values of 
52.7 μM and 341.9 μM.39,40 Recently, low micromolar scale ABAD inhibitors were reported.41 Furthermore, 
a fused bicyclic system comprised of 5- and 6-membered rings (i.e. indane) represents core scaffold of 
several MAO inhibitors (e.g. rasagiline or ladostigil). The carbocyclic system is not exclusive for MAO 
inhibition, since other bicyclic and heterocyclic scaffolds have been reported to inhibit MAO.35,42 In this 
case, the aminoindane moiety has been replaced with an isosteric indole ring (Fig. 1: B) and further 
incorporated into frentizole scaffold (Fig. 1: A). The frentizole urea linker was changed to the analogous 
thiourea linker since the similar thiocarbonyl scaffold was previously identified to be beneficial for ABAD 
inhibition.43 The distal phenyl ring presented in frentizole was modified by various substitution patterns 
that have been introduced to investigate structure and activity relationship of this scaffold (Fig. 1: C). 
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Fig. (1). Conjunctive design approach combining frentizole (A) and ladostigil (B) to novel MAO/ABAD inhibitors (C). 
 
In this study we report the synthesis and in vitro evaluation of a novel series of these indolyl thiourea 
compounds. In vitro evaluation includes the inhibition of the MAO-A, MAO-B and ABAD enzymes in direct 
assays. The inhibition of horseradish peroxidase (HRP, used in the coupled assay for MAO activity) was also 
evaluated, but this inhibition was identified as a confounding factor in the initial evaluation of the novel 
compounds. Acute toxicity was determined via the MTT assay using the CHO-K1 cell line and the most 
promising compounds were selected for a PAMPA assay to evaluate their ability to cross the blood-brain-
barrier (BBB). 
 
2. Results 
2.1. Chemistry 
A two-step synthesis was performed to generate the desired disubstituted indolyl thioureas 3-23. 
Electron-rich aromatic amines were readily converted to the corresponding isothiocyanates (Scheme 1, 
conditions a),44 whereas electron poor aromatic amines required stronger basic conditions (Scheme 1, 
conditions b) to achieve conversion of the amine to a dithiocarbamic salt with following isothiocyanate (2) 
formation.44,45 The isothiocyanates (2) were coupled with 1H-indol-5-amine to generate the disubstituted 
thioureas 3-23 (Table 1) in moderate to excellent yields (38-99%).46 The reverse process with conversion of 
1H-indol-5-amine to isothiocyanate and subsequent coupling step (Scheme 1, conditions d) with the second 
amine was used for final compounds with free phenolic group, where complete conversion to 
dithiocarbamic salt does not proceed quantitatively within reasonable time period. However, the outlined 
process in Scheme 1 was favoured due to higher reactivity of amines in the coupling step (Scheme 1, 
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conditions d), resulting in higher overall yields. The procedure also allowed compounds to be more readily 
purified by subsequent column chromatography rendering final compounds (3-23). The experimental 
section gives a detailed description of which procedure was used for each amine. 
 
 
Scheme 1. Synthesis of indolyl thioureas 3-23. Reagents and conditions: (a) CS2, Et3N, r.t. (b) NaH, CS2, reflux; (c) 
Boc2O, DMAP, 0°C to r.t.; (d) 1H-indole-5-amine, DCM, r.t. 
 
Table 1. Substitution pattern and isolated yields of indolyl thioureas (3-23). 
Comp. Ar 
Yield 
(%) 
 
Comp. Ar 
Yield 
(%) 
 
Comp. Ar 
Yield 
(%) 
3 
 
90 
 
10 
 
93 
 
17 
 
85 
4 
 
61 
 
11 
 
99 
 
18 
 
99 
5 
 
92 
 
12 
 
89 
 
19 
 
38 
6 
 
92 
 
13 
 
99 
 
20 
 
99 
7 
 
84 
 
14 
 
80 
 
21 
 
66 
8 
 
99 
 
15 
 
97 
 
22 
 
90 
9 
 
89 
 
16 
 
99 
 
23 
 
93 
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2.2. Biological activity 
2.2.1. Controls in the coupled assay for MAO reveal HRP inhibition 
An initial screen using a coupled fluorescence assay to assess MAO inhibition by the novel indole 
thiourea compounds suggested potent inhibition in the micromolar range that was not replicated in the 
direct spectrophotometric assay. The coupled assay uses HRP to detect the second MAO product, H2O2, 
resulting in the conversion of 10-acetyl-3,7-dihydroxyphenoxazine to resorufin.47–49 The compounds did not 
quench the fluorescence of resorufin but most of them inhibited HRP by greater than 30% at 50 µM, the 
most potent by >80%. The inhibition of HRP by each compound at 5 or 50 µM is given as Supplementary 
Information (Table S1). The most potent HRP inhibitors, all with IC50 values of around 1 µM, always 
possessed a phenolic group, either in the 4-position (6, 17, 21 and 23) or 2-position (4) of the phenyl ring. 
The phenolic group has previously been associated with HRP inhibition, however on a flavonoid scaffold.50 
In light of these findings, we point out a potential flaw of the coupled Ampliflu™ Red assay, which may 
produce false positive results. In this study, the HRP inhibition at 1 µM prevented the use of the coupled 
assay to evaluate MAO inhibition. 
2.2.2. Monoamine oxidase activity 
To avoid the observed interference issues with the coupled assay, all compounds were evaluated using 
the kynuramine spectrophotometric assay.51 All compounds were soluble in assay buffer at 100 μM but 
absorbed light at the wavelength (314 nm) of the kynuramine assay, limiting the maximum concentration 
to 30 µM for the initial screen. Compounds selected for further study could be used up to 100 μM. IC50 
values were measured for all compounds using purified MAO-A as shown in Table 2. Several compounds 
displayed moderate to low micromolar range of inhibition, allowing selection of compounds for evaluation 
against membrane-bound MAO-A and MAO-B. IC50 values for the selected compounds are given in Table 2. 
The selectivity index calculated based on the IC50 values showed a small selectivity for MAO-B (6, 15, 17, 18 
and 19). 
2.2.3. ABAD activity 
Compounds 3-23 were screened at a fixed 100 µM concentration to evaluate their inhibitory effect on 
ABAD activity with modified spectrophotometric assay.26 The majority of the compounds did not 
significantly inhibit ABAD function. However, compounds 17 and 21 induced a decrease in ABAD activity of 
51% or 61%, respectively (Table 2). Both compounds possess a phenolic group, which appears to be a key 
feature for displaying inhibition of ABAD. Based on the small effects observed in the 100 µM screen, the 
determination of IC50 was not possible since the concentration range needed would exceed the limits of 
assay. 
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Table 2. In vitro and cytotoxicity data for compounds 3-23. 
Compound Ar 
pure MAO-A mb MAO-A mb MAO-B ABAD MTT 
IC50 (µM) 
a IC50 (µM) 
b IC50 (µM) 
b 100 µM c LC50 (µM) 
d 
frentizole - None None None - 31 ± 3 
3 Ph > 30 57.5 ± 12 60 ± 12 85.8 ± 0.5 337 ± 0 
4 2-OH-Ph 39 ± 19 14 ± 2 4.0 ± 0.8 85.0 ± 0.8 509 ± 10 
5 3-OH-Ph None - - 91.6 ± 0.6 977 ± 7 
6 4-OH-Ph None > 100 17 ± 2 90.9 ± 0.6 848 ± 150 
7 4-OHCH2-Ph None - - 84.2 ± 0.5 1080 ± 56 
8 4-MeO-Ph 36 ± 15 36 ± 10 37 ± 11 91.3 ± 0.6 476 ± 28 
9 4-PhO-Ph None - - 90.9 ± 1.6 36 ± 10 
10 4-Br-Ph 5.9 ± 1.3 23 ± 3 58 ± 12 83.0 ± 0.5 220 ± 43 
11 4-MeCO-Ph 67 - - 79.2 ± 0.9 154 ± 12 
12 4-PhCO-Ph None - - 80.4 ± 0.6 20 ± 2 
13 4-COOEt-Ph 71 - - 74.6 ± 1.0 123 ± 6 
14 4-MeCONH-Ph 71 70 ± 13 37 ± 8 93.0 ± 1.0 1040 ± 30 
15 isoquinolin-5-yl 24 ± 5 24 ± 4 4.0 ± 1.1 96.5 ± 0.8 > 400 
16 3,4-MeO-Ph None - - 93.8 ± 0.9 797 ± 116 
17 3-Cl-4-OH-Ph 58 ± 18 58 ± 13 8.6 ± 1.2 49.1 ± 0.5 447 ± 2 
18 2-OH-4-Me-Ph None 24 ± 2 3.2 ± 0.7 87.2 ± 1.2 370 ± 30 
19 2-OH-4-Cl-Ph 39 ± 9 6.3 ± 0.7 0.30 ± 0.12 76.0 ± 0.8 251 ± 2 
20 
3-COOMe-4-
OH-Ph 
None > 100 31 ± 4 90.0 ± 0.8 423 ± 69 
21 3,5-Cl-4-OH-Ph None > 100 17 ± 1 39.0 ± 0.6 523 ± 7 
22 4-MeO-Bn None - - 88.5 ± 1.2 232 ± 10 
23 3,4-OH-Bn None - - 81.5 ± 0.8 471 ± 73 
amph.53 - 17.2 ± 0.2 5.33 ± 0.6 176 ± 45 - - 
a Each IC50 value (± SE of the estimate) comes from 8-12 individual spectrophotometric assays using purified human 
MAO-A. The maximum concentration used was 30 µM. Projected IC50 values above 30 µM are shown without error 
bars, but are given to allow the distinction from those compounds that showed no inhibition (None). 
b Each IC50 value (± SE of the estimate) comes from 8-10 individual spectrophotometric assays using membrane-bound 
(mb) human MAO-A or MAO-B. The maximum concentration used was up to 100 µM. 
c The values are expressed in percentage of remaining enzyme activity ± SEM (values are an average of two biological 
repeats each with three technical repeats). 
d
 The LC50 value refers to 3 independent measurements ± SEM.  
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2.2.4. Cytotoxicity 
To evaluate acute cytotoxicity, all compounds were screened using the standard MTT assay with the 
CHO-K1 cell line which is commonly used for cytotoxicity screening.52 The observed toxicity was expressed 
as LC50 values (Table 2). The majority of the compounds showed very low levels of toxicity with an LC50 
value over 200 µM compared to parent frentizole, producing valuable results for further investigation. Two 
compounds (9 and 12) showed elevated toxicity (LC50 
~20-40 µM) but these compounds didn’t show any 
beneficial biological activity. 
2.2.5. Blood-brain barrier permeation and physicochemical properties 
Penetration across the BBB is an essential property for compounds targeting the CNS. In order to 
predict passive blood-brain penetration of most promising compounds prepared in the current study (10, 
17, 21), a modification of the parallel artificial membrane permeation assay (PAMPA) has been used based 
on reported protocol.54 The penetration value (Pe) was derived mathematically from time-dependent 
changes of the selected compounds’ concentrations in two aqueous phases separated by the artificial 
membrane (see Experimental section). Compounds 10 and 17 showed Pe values greater than 4, which 
indicate sufficient passive transition of the compounds through the BBB (Table 3).55,56 
For the physicochemical properties, the number of hydrogen bond donors (HBD), number of hydrogen 
bond acceptors (HBA), topological polar surface area (TPSA), logarithm of the n-octanol-water partition 
coefficient for non-ionized species (ClogP) and the n-octanol-water distribution coefficient (ClogD) 
reflecting the ratio of the ionic forms at pH = 7.4 have been calculated in ACDLabs PhysChem Suite 12.0 and 
compared with the experimental values of Pe and chromatographic capacity factors k. The three 
compounds 10, 17 and 21 do not violate any of the Lipinski’s rules of five, although Pe values (Table 4) 
apparently follow their own trend showing somewhat ambiguous relationship with k and the in silico 
molecular descriptors. The most striking deviation is exhibited by compound 21 that has a low penetration 
rate Pe despite its sufficient hydrophobicity as implied by relatively high values of ClogP, ClogD and k. This 
finding may results from overall physicochemical effect of 3,5-dichloro-4-hydroxy aromatic moiety (see 
Table 1) which renders 21 the most ionisable compound at the physiological pH of 7.4 in comparison to 10 
and 17. Therefore, it should be noted that the PAMPA (predictive) assay cannot be simplified by high 
performance liquid chromatography analysis or basic molecular descriptors (HBD/HBA, TPSA, ClogP/D), but 
it can be replaced in vivo experiments when the predicted values should be verified. 
 
Table 3. Physical chemical properties of selected compounds. 
Comp. Pe ± SEM
a k ± SEMb HBD/HBAc TPSAc ClogPc ClogD7.4
c 
10 6.9 ± 0.6 4.355 ± 0.000 3/3 71.9 3.57 3.57 
17 7.3 ± 0.2 3.760 ± 0.000 4/4 92.2 3.16 3.12 
21 3.0 ± 0.3 3.975 ± 0.000 4/4 92.2 4.14 3.61 
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a Prediction of blood-brain barrier penetration of drugs expressed as Pe ± SEM (*10
-6 cm.s-1). High BBB permeation 
predicted for Pe > 4; BBB permeation uncertain for Pe between 2.0 and 4.0; low BBB permeation predicted for < 2.0  
b
 Capacity factors k determined by a gradient HPLC method on a reverse C18 stationary phase working in acid polar 
organic mode (pH ~3.5). The values of k given as mean ± SEM of 24 measurements. 
c Calculated in ACDLabs PhysChem Suite 12.0 
 
2.3. Molecular modelling 
A molecular docking study was performed in an attempt to identify the binding modes of compound 19 
within the MAO-A and MAO-B active sites. Flexible docking was performed using AutoDock Vina 1.1.2 and 
the 2Z5X (i.e. MAO-A) and 2V5Z (i.e. MAO-B) protein X-ray structures from the Protein Databank. Figure 2 
shows the top-scored docking pose of compound 19 (-10.3 kcal/mol) located within the MAO-A cavity. 
Compound 19 was predicted to bind below the flavin moiety of the FAD cofactor. The indole five-
membered ring of 19 displays alignment with Tyr407 phenyl ring supporting the formation of π-π stacking 
interaction (3.8 Å). The orientation of the N-indole hydrogen towards oxygen of Tyr444 phenolic group 
suggests further indole ring stabilization via hydrogen bonding (2.1 Å). A secondary weak hydrogen bond 
may also be formed between the thiourea nitrogen and amid hydrogen of Gln215 which are in near 
proximity (2.2 Å). Lastly, the distant 4-chloro-2-hydroxyphenyl ring of 19 is oriented towards the aromatic 
cycle of Phe208 suggesting the potential for a weak T-shaped π-π interaction (3.9 Å), where the para 
positioned chlorine points to a hydrophobic cavity formed by Leu97, Ala111 and Ile325 (pocket surface not 
shown for clarity of the figure). More or less similar interactions were revealed in the top-scored mode of 
compound 19 within the active site of MAO-B (-10.3 kcal/mol) (Fig. 3). In contrast to MAO-A, the indole 
moiety of 19 was stacked between Tyr435 (3.9 Å) and Tyr398 (3.7 Å) without involvement of the indole 
hydrogen in any polar interactions. Interestingly, the 2-hydroxy moiety of 19 was stabilized by H-bond 
interactions with hydroxyl of Tyr326 (2.5 Å) and terminal amide hydrogen of Gln206 (2.9 Å). Although the 
best docking scores of compound 19 in MAO-A/B do not suggest any significant binding preference for 
either of the enzymes, the calculations provided 9 energetically similar binding modes of compound 19 in 
MAO-B cavity, whilst in MAO-A cavity only 2 binding modes were found. However, the reason for the lack 
of thermodynamic explanation for the different IC50 values for MAO-A and MAO-B is still not obvious. 
Compounds can often bind with either end of the molecule close to the flavin in MAO,57 or in rotated 
configuration.58 In the latter article, molecular dynamics were used to understand a change in affinity, but 
that is beyond the scope of this exploratory study for these relatively weak inhibitors of MAO. 
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Fig. (2). Superimposition of 19 (-10.3 kcal/mol) in the active site MAO-A (PDB ID: 2Z5X). The ligand is shown as blue 
sticks, selected MAO-A residues as magenta sticks, flavin cofactor as yellow sticks and the backbone as light grey 
cartoon. For the sake of clarity, only four of residues are displayed. 
 
Fig. (3). Superimposition of 19 (-10.3 kcal/mol) in the active site MAO-B (PDB ID: 2V5Z). Ligand is shown as blue sticks, 
selected MAO-B residues as magenta sticks, flavin cofactor as yellow sticks and the backbone as light grey cartoon. For 
the sake of clarity, only four of residues are displayed. 
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3. Structure-activity relationship 
Initial evaluation of the compounds on the activity of purified MAO-A identified only compound 10 
(para-Br) as giving significant inhibition, with an IC50 value of 5.9 µM for purified human MAO-A, but several 
other (mainly para) substitutions were found on µM level (4, 8, 15, 17, 19). On the other hand, the 
introduction of a second phenyl ring connected via an ether (9) or a carbonyl moiety (12) resulted in the 
loss of activity, indicating the space limitation for the favoured para substituent. In contrast, isoquinolin-5-
yl moiety (15) displayed promising inhibition.  
For the selected compounds studied on both membrane-bound MAO-A and B, non-selective inhibition 
was observed only for the parent compound 3 (IC50 around 60 µM), and with the para-methoxy substituent 
8 (IC50 around 36 µM). All other compounds were more selective for MAO-B. MAO-A inhibition was 
retained for ortho-hydroxyl-containing compounds (4, 19) particularly with additional chlorine in the para 
(19) or meta position (17, 19) and also for small lipophilic substitutions such as methoxy moiety (8), 
although with higher IC50. The substituents generally improved inhibition of MAO-B. In the para position, 
the hydroxy moiety improved inhibition of MAO-B by 4-fold (17 versus 3). The ortho hydroxyl (4) improved 
binding to MAO-B by 15-fold (compared to only 4-fold on MAO-A) giving an IC50 decrease to 4 µM. With the 
ortho-hydroxyl present, para substitution with chlorine improved MAO-B inhibition to 0.3 µM (19), 10-fold 
better than a methyl substituent (18). In contrast, the para bromine moiety was favoured for MAO-A but 
not MAO-B inhibition (10 versus 3). 
For inhibition of ABAD activity, compounds 17 and 21 were the most potent with a 4-hydroxy 
substitution and additionally chlorine on the distal phenyl ring. The 4-hydroxy moiety alone (6) gave 
inhibition comparable with other positioned isomers (4 and 5) and not much better than 3 without the 
hydroxyl group. The introduction of chlorine into the C-3 position (17) increased the inhibitory effect. 
Additionally, a second chlorine present in the C-5 position (21) further increased the inhibitory effect, which 
is in agreement with recently reported findings.41 Functional groups other than chlorine (20 and 23) were 
not beneficial. Comparing the discussed compounds with the previously published 
urea/thiourea/phosphonate series, it shows that the inhibition ability doesn’t vary significantly with the 
linker changes.38–40 On the other hand, the bicyclic aromatic scaffold using substituted benzothiazole or 
other moiety might be a crucial factor. In this case, the introduction of indole moiety seems to be rather 
unfavourable for ABAD inhibitory ability if compared to previously used benzothiazoles.38–41 This fact might 
be related to either its flipped position and/or missing substitution of the indolyl scaffold, which will be the 
matter of further investigation.  
Taken together, the best MAO and ABAD inhibitors from presented series of compounds do not 
possess the same structural features required for inhibition of both enzymes, when ABAD inhibition seems 
to be restricted to the 3-chlorine-4-hydroxy or 3,5-chlorine-4-hydroxy scaffold. The presence of the 
phenolic moiety particularly influenced the activity on the MAO targets. An improved MAO inhibitory ability 
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(with a degree of MAO-B selectivity) was shown in a decrease of IC50 with presence of ortho-hydroxy group 
(3 versus 4), with an additional para-substitution with chlorine pushing the IC50 to low micromolar (MAO-A) 
and high nanomolar values (MAO-B) for compound 19. In contrast, the most active ABAD inhibitors have 
the phenolic group restricted to the para-position of the distal phenyl ring, with improvement due to meta-
substitution (single or double chlorine moiety). 
Importantly, the majority of the tested MAO/ABAD inhibitors shared a low cytotoxic profile (usually 
one order of magnitude better) compared to parent compound frentizole. Only two compounds (9 and 12) 
showed higher cytotoxicity, possibly associated with their increased lipophilicity, since they contain an 
additional phenyl ring connected via ether or carbonyl linker. However, compounds 9 and 12 did not show 
biological activity valuable for further investigation. 
4. Conclusion 
In summary, a novel class of disubstituted thioureas was synthesized and evaluated for MAO-A, MAO-B 
and ABAD inhibitory ability and a cytotoxicity profile.  Some compounds showed MAO inhibitory activity in 
the micromolar range (mostly with modest MAO-B selectivity), expanding the pool of known MAO 
inhibitors scaffolds. In case of ABAD, the molecular design was only partially successful in retaining ABAD 
inhibitory ability, with only two compounds showed promising structural features for ABAD inhibition. The 
majority of the compounds also exhibited HRP inhibitory properties, demonstrating the limitations for the 
use of the HRP-coupled assay, particularly with compounds possessing phenolic groups. Therefore, we 
emphasize caution when using coupled enzymatic reactions such as the Amplex™/Ampliflu™ Red assay, and 
the need to validate positive results with direct or different assays to avoid misconceptions in data 
interpretation. 
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5. Experimental section 
5.1. Synthesis 
5.1.1. Chemicals and instrumentation 
All reagents and solvents were purchased from commercial sources (Sigma Aldrich, Merck) and they 
were used without any further purification. Thin-layer chromatography for reaction monitoring was 
performed on Merck aluminium sheets, silica gel 60 F254. NMR spectra (
1H and 13C) were acquired at 
500/125 MHz on a Varian S500 spectrometer or at 300/75 MHz on a Varian Gemini 300 spectrometer. 
Chemical shifts δ are given in ppm and referenced to the signal center of solvent peaks DMSO-d6 (δ 
2.50 ppm and 39.52 ppm for 1H and 13C, respectively). Coupling constants are expressed in Hz. High 
resolution mass spectra (HRMS) were recorded by coupled LCMS system consisting of Dionex UltiMate 
3000 analytical LC system and Q Exactive Plus hybrid quadrupole-orbitrap spectrometer. As an ion-source, 
heated electro-spray ionization (HESI) was utilized (setting: sheath gas flow rate 40, aux gas flow rate 10, 
sweep gas flow rate 2, spray voltage 3.2 kV, capillary temperature 350°C, aux gas temperature 300°C, S-lens 
RF level 50. Positive ions were monitored in the range of 100-1500 m/z with the resolution set to 140 000. 
Obtained mass spectra were processed in Xcalibur 3.0.63 software. Uncalibrated purity > 95% at 254nm 
was confirmed for all the studied compounds by HPLC. Elemental analyses were carried out with CE 
Instruments EA-1110 CHN (CE Instruments, Wigan, UK). Melting points were determined on a Stuart SMP30 
melting point apparatus and are uncorrected. 
 
5.1.2. General procedure for the synthesis of isothiocyanates for electron rich aromatic amines (2). 
This procedure was employed to generate corresponding isothiocyanates for final thioureas 3-9 and 
14-23. The reverse process, where 1H-indole-5-isothiocyanate was firstly generated followed by 
subsequent coupling with corresponding amine, was used for final thioureas with free phenolic groups (4-7, 
17, 19, 21 and 23). 
An amine (1; 3 mmol) was dissolved in THF (5 mL). While stirring, CS2 (30 mmol, 2.28 g, 1.80 mL) and 
Et3N (3 mmol, 0.30 g, 0.42 mL) were added. After the complete conversion to dithiocarbamic acid salt 
(monitored via TLC, generally within 30-60 min), the reaction mixture was cooled on an ice bath with 
immediate addition of Boc2O (2.97 mmol, 0.65 g, 1 mL THF solution) and DMAP (0.03 mmol, 11 mg, 0.5 mL 
THF solution). Complete consumption of dithiocarbamic acid salt proceeded within 15-60 min. Solvent and 
other volatiles were removed under reduced pressure yielding isothiocyanate (2) quantitatively (TLC) and 
used in next step without further purification.44 
 
5.1.3. General procedure for the synthesis of isothiocyanates electron poor aromatic amines (2). 
This procedure was employed to generate corresponding isothiocyanates for final thioureas 10-13. 
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An amine (1; 3 mmol) was dissolved in THF (10 mL) and cooled on an ice bath. NaH (60% in mineral oil; 
1.5 mmol, 0.18 g) was added and mixture was stirred for next 10 min on an ice bath. CS2 (9 mmol, 0.69 g, 
0.54 mL) was added drop-wise and the reaction was allowed to reach room temperature. The mixture was 
refluxed for 18 h and then cooled on an ice bath. Boc2O (2.97 mmol, 0.65 g, 1 mL THF solution) and DMAP 
(0.03 mmol, 11 mg, 0.5 mL THF solution) were added. The mixture was stirred for next 60 min at room 
temperature. The solution was acidified with 1 N HCl (15 mL) and extracted with Et2O (3×20 mL). The 
combined organic layers were dried (Na2SO4) and the solvent was removed under reduced pressure. The 
residue was purified by column chromatography (silica gel, heptane-EtOAc, 5:1) to afford isothiocyanate 
(2), which was directly used in next step.44,45 
 
5.1.4. General procedure for the synthesis of 1-aryl-3-(1H-indol-5-yl)thiourea (3-23): 
The aromatic amine (1 mmol) was dissolved in DCM (5 mL). Solution of isothiocyanate (1 mmol) in 
DCM (2 mL) was added drop-wise and the mixture was stirred for 20 h at room temperature.46 Solvent was 
removed under reduced pressure and the residue was purified by column chromatography (silica gel, 
CHCl3-MeOH) to yield corresponding product. Compounds were recrystallized from Et2O-EtOAc to yield final 
thiourea. 
1-(1H-indol-5-yl)-3-phenylthiourea (3) 
Light-yellow solid, yield 0.24 g (90%), mp 159-160 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.10 (s, 1H), 9.67 
(s, 1H), 9.45 (s, 1H), 7.55 (d, J = 1.5 Hz, 1H), 7.50 (d, J = 7.5 Hz, 2H), 7.39 – 7.34 (m, 2H), 7.33 – 7.28 (m, 2H), 
7.13 – 7.05 (m, 2H), 6.45 – 6.40 (m, 1H). 13C NMR (125 MHz, DMSO-d6) δ 179.96, 139.81, 133.88, 130.54, 
128.21, 127.53, 126.06, 124.12, 123.78, 119.47, 116.40, 111.23, 101.28. HRMS (HESI) calcd for C15H14N3S 
[M+H]+ 268.09029, found 268.09042. Anal. calcd for C15H13N3S: C, 67.39; H, 4.90; N, 15.72; S, 11.99. Found 
C, 67.15; H, 5.04; N, 15.49; S, 12.05. 
1-(2-hydroxyphenyl)-3-(1H-indol-5-yl)thiourea (4) 
Beige solid, yield 0.17 g (61%), mp 137-138 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.15 (s, 1H), 9.86 (s, 
1H), 9.75 (s, 1H), 8.76 (s, 1H), 8.14 (d, J = 7.7 Hz, 1H), 7.58 (s, 1H), 7.45 – 7.32 (m, 2H), 7.08 (d, J = 8.5 Hz, 
1H), 6.99 – 6.89 (m, 1H), 6.87 – 6.71 (m, 2H), 6.44 (s, 1H). 13C NMR (75 MHz, DMSO-d6) δ 178.95, 148.80, 
134.04, 129.96, 127.66, 127.14, 126.29, 124.81, 124.25, 119.56, 118.41, 116.71, 115.09, 111.53, 101.35. 
HRMS (HESI) calcd for C15H14N3OS [M+H]
+ 284.08521, found 284.08502. Anal. calcd for C15H13N3OS: C, 63.58; 
H, 4.62; N, 14.83; S, 11.31. Found C, 63.25; H, 4.88; N, 14.51; S, 11.27. 
1-(3-hydroxyphenyl)-3-(1H-indol-5-yl)thiourea (5) 
Off-white solid, yield 0.26 g (92%), mp 102-104 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.08 (s, 1H), 9.57 
(s, 1H), 9.39 (s, 2H), 7.54 (d, J = 1.6 Hz, 1H), 7.38 – 7.33 (m, 2H), 7.11 – 7.05 (m, 2H), 7.04 (t, J = 2.1 Hz, 1H), 
6.87 (dd, J = 8.0, 1.1 Hz, 1H), 6.53 – 6.49 (m, 1H), 6.44 – 6.40 (m, 1H). 13C NMR (125 MHz, DMSO-d6) δ 
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179.69, 157.32, 140.71, 133.83, 130.71, 129.00, 127.48, 126.02, 119.53, 116.37, 114.00, 111.26, 111.12, 
110.42, 101.26. HRMS (HESI) calcd for C15H14N3OS [M+H]
+ 284.08521, found 284.08505. Anal. calcd for 
C15H13N3OS: C, 63.58; H, 4.62; N, 14.83; S, 11.31. Found C, 63.23; H, 4.55; N, 14.56; S, 11.02. 
1-(4-hydroxyphenyl)-3-(1H-indol-5-yl)thiourea (6) 
Off-white solid, yield 0.26 g (92%), mp 188-190 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.07 (s, 1H), 9.40 
(s, 1H), 9.30 (br s, 1H), 9.15 (s, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.37 – 7.32 (m, 2H), 7.22 – 7.15 (m, 2H), 7.05 
(dd, J = 8.6, 2.0 Hz, 1H), 6.75 – 6.68 (m, 2H), 6.44 – 6.39 (m, 1H). 13C NMR (125 MHz, DMSO-d6) δ 180.31, 
154.70, 133.85, 130.86, 130.69, 127.52, 126.47, 126.00, 119.66, 116.53, 114.85, 111.17, 101.27. HRMS 
(HESI) calcd for C15H14N3OS [M+H]
+ 284.08521, found 284.08514. Anal. calcd for C15H13N3OS: C, 63.58; H, 
4.62; N, 14.83; S, 11.31. Found C, 63.29; H, 4.83; N, 14.61; S, 11.58. 
1-(4-(hydroxymethyl)phenyl)-3-(1H-indol-5-yl)thiourea (7) 
Light-brown solid, yield 0.25 g (84%), mp 151-152 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.10 (s, 1H), 9.62 
(s, 1H), 9.41 (s, 1H), 7.55 (s, 1H), 7.46 – 7.40 (m, 2H), 7.39 – 7.33 (m, 2H), 7.29 – 7.22 (m, 2H), 7.08 (dd, J = 
8.6, 1.8 Hz, 1H), 6.43 (s, 1H), 5.14 (t, J = 5.7 Hz, 1H), 4.46 (d, J = 5.7 Hz, 2H). 13C NMR (125 MHz, DMSO-d6) δ 
180.04, 138.48, 138.32, 133.89, 130.58, 127.54, 126.44, 126.07, 123.74, 119.53, 116.44, 111.24, 101.30, 
62.64. HRMS (HESI) calcd for C16H16N3OS [M+H]
+ 298.10086, found 298.10074. Anal. calcd for C16H15N3OS: C, 
64.62; H, 5.08; N, 14.13; S, 10.78. Found C, 64.36; H, 5.04; N, 13.92; S, 11.02. 
1-(1H-indol-5-yl)-3-(4-methoxyphenyl)thiourea (8) 
Off-white solid, yield 0.30 g (99%), mp 157-158 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.09 (s, 1H), 9.50 
(s, 1H), 9.24 (s, 1H), 7.53 (d, J = 1.8 Hz, 1H), 7.39 – 7.30 (m, 4H), 7.06 (dd, J = 8.6, 1.8 Hz, 1H), 6.92 – 6.85 (m, 
2H), 6.42 (s, 1H), 3.74 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 180.29, 156.38, 133.86, 132.54, 130.59, 
127.53, 126.18, 126.02, 119.57, 116.48, 113.46, 111.21, 101.26, 55.19. HRMS (HESI) calcd for C16H16N3OS 
[M+H]+ 298.10086, found 298.10068. Anal. calcd for C16H15N3OS: C, 64.62; H, 5.08; N, 14.13; S, 10.78. Found 
C, 64.40; H, 5.10; N, 13.98; S, 10.98. 
1-(1H-indol-5-yl)-3-(4-phenoxyphenyl)thiourea (9) 
Beige solid, yield 0.32 g (89%), mp 180-181 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.10 (s, 1H), 9.64 (s, 
1H), 9.42 (s, 1H), 7.53 (d, J = 1.1 Hz, 1H), 7.49 – 7.44 (m, 2H), 7.41 – 7.33 (m, 4H), 7.12 (t, J = 7.4 Hz, 1H), 
7.06 (dd, J = 8.6, 1.9 Hz, 1H), 7.01 – 6.94 (m, 4H), 6.44 – 6.40 (m, 1H). 13C NMR (125 MHz, DMSO-d6) δ 
180.13, 157.07, 152.97, 135.38, 133.89, 130.53, 129.97, 127.53, 126.06, 125.97, 123.15, 119.52, 118.66, 
118.15, 116.47, 111.23, 101.27. HRMS (HESI) calcd for C21H18N3OS [M+H]
+ 360.11651, found 360.11618. 
Anal. calcd for C21H17N3OS: C, 70.17; H, 4.77; N, 11.69; S, 8.92. Found C, 69.88; H, 4.96; N, 11.47; S, 9.19. 
1-(4-bromophenyl)-3-(1H-indol-5-yl)thiourea (10) 
Beige solid, yield 0.32 g (93%), mp 190-191 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.78 (s, 
1H), 9.52 (s, 1H), 7.53 (d, J = 1.4 Hz, 1H), 7.48 (s, 4H), 7.39 – 7.34 (m, 2H), 7.06 (dd, J = 8.6, 2.0 Hz, 1H), 6.44 
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– 6.41 (m, 1H). 13C NMR (125 MHz, DMSO-d6) δ 179.90, 139.33, 133.93, 130.94, 130.36, 127.54, 126.11, 
125.73, 119.40, 116.41, 116.04, 111.29, 101.30. HRMS (HESI) calcd for C15H13BrN3S [M+H]
+ 346.00081, 
found 346.00082. Anal. calcd for C15H12BrN3S: C, 52.03; H, 3.49; N, 12.14; S, 9.26. Found C, 52.13; H, 3.40; N, 
12.25; S, 9.48. 
1-(4-acetylphenyl)-3-(1H-indol-5-yl)thiourea (11) 
Light-yellow solid, yield 0.33 g (99%), mp 163-164 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.12 (s, 1H), 9.99 
(s, 1H), 9.89 (s, 1H), 7.93 – 7.88 (m, 2H), 7.76 – 7.71 (m, 2H), 7.58 (s, 1H), 7.40 – 7.35 (m, 2H), 7.09 (dd, J = 
8.6, 1.9 Hz, 1H), 6.45 – 6.41 (m, 1H), 2.54 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 196.57, 179.59, 144.59, 
133.94, 131.82, 130.40, 128.74, 127.51, 126.14, 121.66, 119.26, 116.24, 111.28, 101.31, 26.48. HRMS (HESI) 
calcd for C17H16N3OS [M+H]
+ 310.10086, found 310.10062. Anal. calcd for C17H15N3OS: C, 66.00; H, 4.89; N, 
13.58; S, 10.36. Found C, 66.25; H, 5.11; N, 13.43; S, 10.11. 
1-(4-benzoylphenyl)-3-(1H-indol-5-yl)thiourea (12) 
White solid, yield 0.33 g (89%), mp 198-199 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.13 (s, 1H), 9.99 (s, 
1H), 9.91 (s, 1H), 7.80 – 7.75 (m, 2H), 7.74 – 7.69 (m, 4H), 7.66 (t, J = 7.4 Hz, 1H), 7.60 – 7.53 (m, 3H), 7.41 – 
7.35 (m, 2H), 7.10 (dd, J = 8.6, 1.4 Hz, 1H), 6.46 – 6.42 (m, 1H). 13C NMR (125 MHz, DMSO-d6) δ 194.58, 
179.58, 144.38, 137.54, 133.95, 132.23, 131.51, 130.41, 129.34, 128.47, 127.52, 126.16, 121.65, 119.26, 
116.25, 111.28, 101.32. HRMS (HESI) calcd for C22H18N3OS [M+H]
+ 372.11651, found 372.11627. Anal. calcd 
for C22H17N3OS: C, 71.14; H, 4.61; N, 11.31; S, 8.63. Found C, 70.92; H, 4.67; N, 11.13; S, 8.32. 
Ethyl 4-(3-(1H-indol-5-yl)thioureido)benzoate (13) 
Off-white solid, yield 0.36 g (99%), mp 149-150 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.12 (s, 1H), 9.94 
(s, 1H), 9.82 (br s, 1H), 7.93 – 7.86 (m, 2H), 7.75 – 7.69 (m, 2H), 7.57 (s, 1H), 7.41 – 7.33 (m, 2H), 7.09 (dd, J 
= 8.6, 1.6 Hz, 1H), 6.46 – 6.41 (m, 1H), 4.29 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H). 13C NMR (125 MHz, 
DMSO-d6) δ 179.64, 165.38, 144.56, 133.96, 130.36, 129.50, 127.52, 126.15, 124.41, 121.92, 119.30, 
116.31, 111.29, 101.32, 60.41, 14.22. HRMS (HESI) calcd for C18H18N3O2S [M+H]
+ 340.11142, found 
340.11133. Anal. calcd for C18H17N3O2S: C, 63.70; H, 5.05; N, 12.38; S, 9.45. Found C, 63.53; H, 5.12; N, 
12.13; S, 9.68. 
N-(4-(3-(1H-indol-5-yl)thioureido)phenyl)acetamide (14) 
Beige solid, yield 0.26 g (80%), mp 172-174 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.09 (s, 1H), 9.90 (s, 
1H), 9.56 (s, 1H), 9.33 (s, 1H), 7.58 – 7.46 (m, 3H), 7.42 – 7.29 (m, 4H), 7.06 (d, J = 8.4 Hz, 1H), 6.42 (s, 1H), 
2.03 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 180.04, 168.05, 135.92, 134.71, 133.89, 130.58, 127.54, 
126.05, 124.71, 119.58, 118.91, 116.50, 111.22, 101.29, 23.92. HRMS (HESI) calcd for C17H17N4OS [M+H]
+ 
325.11176, found 325.11176. Anal. calcd for C17H16N4OS: C, 62.94; H, 4.97; N, 17.27; S, 9.88. Found C, 
62.71; H, 5.01; N, 16.99; S, 10.12. 
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1-(1H-indol-5-yl)-3-(isoquinolin-5-yl)thiourea (15) 
Beige solid, yield 0.31 g (97%), mp 213-214 °C. 1H NMR (300 MHz, DMSO-d6) δ 11.13 (s, 1H), 9.85 (s, 
1H), 9.61 (s, 1H), 9.33 (s, 1H), 8.55 (d, J = 5.6 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.89 – 7.74 (m, 2H), 7.72 – 7.56 
(m, 2H), 7.46 – 7.30 (m, 2H), 7.15 (d, J = 8.1 Hz, 1H), 6.45 (s, 1H). 13C NMR (75 MHz, DMSO-d6) δ 181.64, 
152.47, 142.78, 135.16, 134.09, 132.70, 130.47, 129.40, 128.96, 127.62, 127.14, 126.16, 125.92, 119.79, 
116.95, 116.38, 111.39, 101.37. HRMS (HESI) calcd for C18H15N4S [M+H]
+ 319.10119, found 319.10117. Anal. 
calcd for C18H14N4S: C, 67.90; H, 4.43; N, 17.60; S, 10.07. Found C, 67.67; H, 4.24; N, 17.33; S, 9.80. 
1-(3,4-dimethoxyphenyl)-3-(1H-indol-5-yl)thiourea (16) 
Off-white solid, yield 0.34 g (99%), mp 152.5-153.5 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.09 (s, 1H), 
9.49 (s, 1H), 9.27 (s, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.38 – 7.32 (m, 2H), 7.14 (d, J = 2.3 Hz, 1H), 7.06 (dd, J = 
8.6, 2.0 Hz, 1H), 6.93 (dd, J = 8.6, 2.3 Hz, 1H), 6.89 (d, J = 8.6 Hz, 1H), 6.44 – 6.40 (m, 1H), 3.74 (s, 3H), 3.73 
(s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 180.04, 148.23, 146.01, 133.89, 132.72, 130.61, 127.52, 126.03, 
119.66, 116.59, 116.54, 111.53, 111.19, 109.54, 101.27, 55.70, 55.47. HRMS (HESI) calcd for C17H18N3O2S 
[M+H]+ 328.11142, found 328.11111. Anal. calcd for C17H17N3O2S: C, 62.37; H, 5.23; N, 12.83; S, 9.79. Found 
C, 62.11; H, 5.37; N, 12.59; S, 10.01. 
1-(3-chloro-4-hydroxyphenyl)-3-(1H-indol-5-yl)thiourea (17) 
Light-brown solid, yield 0.27 g (85%), mp 152-153 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.09 (s, 1H), 
10.02 (s, 1H), 9.58 (s, 1H), 9.22 (s, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.44 (d, J = 2.5 Hz, 1H), 7.38 – 7.32 (m, 2H), 
7.14 (dd, J = 8.7, 2.5 Hz, 1H), 7.04 (dd, J = 8.6, 1.9 Hz, 1H), 6.90 (d, J = 8.7 Hz, 1H), 6.45 – 6.40 (m, 1H). 13C 
NMR (125 MHz, DMSO-d6) δ 180.29, 150.25, 133.93, 131.84, 130.44, 127.56, 126.47, 126.07, 124.97, 
119.59, 118.59, 116.59, 115.90, 111.27, 101.30. HRMS (HESI) calcd for C15H13ClN3OS [M+H]
+ 318.04624, 
found 318.04614. Anal. calcd for C15H12ClN3OS: C, 56.69; H, 3.81; N, 13.22; S, 10.09. Found C, 56.91; H, 4.01; 
N, 12.95; S, 10.29. 
1-(2-hydroxy-4-methylphenyl)-3-(1H-indol-5-yl)thiourea (18) 
Light-yellow solid, yield 0.27 g (99%), mp 143.5-144.5 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.13 (s, 1H), 
9.74 (s, 1H), 9.60 (br s, 1H), 8.68 (br s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.57 (s, 1H), 7.43 – 7.34 (m, 2H), 7.08 (dd, 
J = 8.6, 1.8 Hz, 1H), 6.65 (s, 1H), 6.58 (d, J = 8.2 Hz, 1H), 6.43 (s, 1H), 2.20 (s, 3H). 13C NMR (125 MHz, DMSO-
d6) δ 179.03, 148.95, 134.35, 134.00, 130.08, 127.64, 126.23, 124.55, 124.48, 119.56, 119.05, 116.66, 
115.79, 111.46, 101.32, 20.71. HRMS (HESI) calcd for C16H16N3OS [M+H]
+ 298.10086, found 298.10065. Anal. 
calcd for C16H15N3OS: C, 64.62; H, 5.08; N, 14.13; S, 10.78. Found C, 64.48; H, 5.18; N, 13.89; S, 10.94. 
1-(4-chloro-2-hydroxyphenyl)-3-(1H-indol-5-yl)thiourea (19) 
Beige solid, yield 0.12 g (38%), mp 150-151 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.14 (s, 1H), 10.31 (s, 
1H), 9.93 (s, 1H), 8.76 (br s, 1H), 8.14 (d, J = 7.9 Hz, 1H), 7.58 (s, 1H), 7.47 – 7.31 (m, 2H), 7.08 (d, J = 7.8 Hz, 
1H), 6.93 – 6.73 (m, 2H), 6.44 (s, 1H). 13C NMR (125 MHz, DMSO-d6) δ 179.12, 150.04, 134.05, 129.92, 
128.12, 127.62, 126.42, 126.27, 125.58, 119.51, 118.11, 116.69, 114.75, 111.48, 101.33. HRMS (HESI) calcd 
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for C15H13ClN3OS [M+H]
+ 318.04624, found 318.04617. Anal. calcd for C15H12ClN3OS: C, 56.69; H, 3.81; N, 
13.22; S, 10.09. Found C, 56.44; H, 3.56; N, 13.39; S, 10.38. 
Methyl 5-(3-(1H-indol-5-yl)thioureido)-2-hydroxybenzoate (20) 
White solid, yield 0.35 g (99%), mp 137-138 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1H), 10.36 (s, 
1H), 9.67 (s, 1H), 9.29 (s, 1H), 7.81 (d, J = 2.3 Hz, 1H), 7.57 (dd, J = 8.8, 2.5 Hz, 1H), 7.51 (s, 1H), 7.40 – 7.33 
(m, 2H), 7.07 – 7.01 (m, 1H), 6.94 (d, J = 8.8 Hz, 1H), 6.43 (s, 1H), 3.89 (s, 3H). 13C NMR (125 MHz, DMSO-d6) 
δ 180.47, 168.93, 157.17, 134.00, 133.29, 131.58, 130.24, 127.61, 126.21, 126.10, 119.56, 116.92, 116.65, 
112.18, 111.37, 101.31, 52.48. HRMS (HESI) calcd for C17H16N3O3S [M+H]
+ 342.09069, found 342.09082. 
Anal. calcd for C17H15N3O3S: C, 59.81; H, 4.43; N, 12.31; S, 9.39. Found C, 59.68; H, 4.76; N, 12.02; S, 9.71. 
1-(3,5-dichloro-4-hydroxyphenyl)-3-(1H-indol-5-yl)thiourea (21) 
Beige solid, yield 0.22 g (66%), mp 174-175 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.94 (s, 
1H), 9.79 (s, 1H), 9.34 (s, 1H), 7.50 (d, J = 0.9 Hz, 1H), 7.46 (s, 2H), 7.40 – 7.32 (m, 2H), 7.03 (dd, J = 8.6, 1.8 
Hz, 1H), 6.44 – 6.40 (m, 1H). 13C NMR (125 MHz, DMSO-d6) δ 180.14, 145.94, 134.01, 132.68, 130.16, 
127.59, 126.13, 124.89, 121.36, 119.50, 116.62, 111.37, 101.32. HRMS (HESI) calcd for C15H12Cl2N3OS 
[M+H]+ 352.00726, found 352.00729. Anal. calcd for C15H11Cl2N3OS: C, 51.15; H, 3.15; N, 11.93; S, 9.10. 
Found C, 51.41; H, 3.37; N, 11.68; S, 9.35. 
1-(1H-indol-5-yl)-3-(4-methoxybenzyl)thiourea (22) 
Beige solid, yield 0.28 g (90%), mp 155-156 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.42 (s, 
1H), 7.69 (br s, 1H), 7.44 (s, 1H), 7.39 – 7.33 (m, 2H), 7.25 (d, J = 8.5 Hz, 2H), 6.95 (dd, J = 8.5, 1.4 Hz, 1H), 
6.88 (d, J = 8.5 Hz, 2H), 6.42 (s, 1H), 4.64 (d, J = 5.4 Hz, 2H), 3.73 (s, 3H). 13C NMR (125 MHz, DMSO-d6) δ 
180.97, 158.16, 134.02, 131.38, 129.73, 128.66, 127.72, 126.17, 119.62, 116.84, 113.56, 111.60, 101.30, 
55.03, 46.78. HRMS (HESI) calcd for C17H18N3OS [M+H]
+ 312.11651, found 312.11636. Anal. calcd for 
C17H17N3OS: C, 65.57; H, 5.50; N, 13.49; S, 10.30. Found C, 65.29; H, 5.60; N, 13.37; S, 10.40. 
1-(3,4-dihydroxybenzyl)-3-(1H-indol-5-yl)thiourea (23) 
Light-brown solid, yield 0.29 g (93%), mp 50-51 °C. 1H NMR (500 MHz, DMSO-d6) δ 11.10 (s, 1H), 9.38 
(s, 1H), 8.85 (br s, 1H), 8.71 (br s, 1H), 7.57 (br s, 1H), 7.45 (s, 1H), 7.39 – 7.31 (m, 2H), 6.96 (dd, J = 8.5, 1.8 
Hz, 1H), 6.74 (d, J = 1.7 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 6.56 (dd, J = 8.0, 1.5 Hz, 1H), 6.42 – 6.38 (m, 1H), 
4.54 (d, J = 5.1 Hz, 2H). 13C NMR (125 MHz, DMSO-d6) δ 180.83, 145.01, 144.16, 133.97, 130.09, 129.85, 
127.70, 126.17, 119.58, 118.35, 116.72, 115.24, 114.99, 111.55, 101.30, 47.13. HRMS (HESI) calcd for 
C16H16N3O2S [M+H]
+ 314.09577, found 314.09558. Anal. calcd for C16H15N3O2S: C, 61.32; H, 4.82; N, 13.41; S, 
10.23. Found C, 61.05; H, 5.03; N, 13.12; S, 10.36. 
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5.2. In vitro evaluation 
Ampliflu™ Red (10-acetyl-3,7-dihydroxyphenoxazine), kynuramine, horseradish peroxidase, human 
MAO-A and MAO-B (expressed in insect cell membranes) were purchased from Sigma-Aldrich. Human 
MAO-A from heterologous expression in yeast was purified as previously reported.51 Compounds were 
dissolved in DMSO and stored in glass vials at 4°C in the dark. Control and inhibitor assays contained the 
same amount of DMSO (1% (v/v)). A multi-mode microplate reader (Molecular Devices FilterMax F5) was 
used for fluorometric assays with HRP and Ampliflu™ Red. A Uvikon 2101 spectrophotometer was used for 
absorbance assays with MAO-A and MAO-B. The IC50 values for selected compounds were determined by 
plotting remaining activity of enzyme against the log of compound concentration. Data analysis was 
performed with GraphPad Prism 5 software using the three parameter equation. 
5.2.1. Fluorescence quenching and horseradish peroxidase activity assay 
No fluorescence quenching of resorufin (1 µM and 10 µM) was observed in the presence of tested 
compounds (50 µM). Additionally, an inhibitory effect on HRP was evaluated using modified Ampliflu™ Red, 
where a direct HRP substrate (H2O2) was used instead of in-situ MAO-generated H2O2.
47,49,59 The assay 
mixture with a final volume of 200 µL 50 mM potassium phosphate buffer (pH 7.4) in the well contained; 
H2O2 (20 µM), Ampliflu™ Red (20 µM) and HRP (0.02 U/mL) and a single compound of interest (50 µM or 
5 µM, 1% DMSO (v/v)). The control wells contained same amount of DMSO (1% (v/v)) without any inhibitor. 
Fluorometric determination of the remaining HRP activity was followed by the fluorescence of the resorufin 
formed (excitation at 535 nm, emission at 595 nm) at 30°C.  
5.2.2. Monoamine oxidase activity assay 
The spectrophotometric assays for purified human MAO-A and for membrane-bound human MAO-
A/MAO-B are based on the conversion of kynuramine to 4-hydroxyquinoline using reported conditions.51,60 
The spectrophotometric assay for purified human MAO-A activity in a final volume of 200 µL 50 mM 
potassium phosphate buffer (pH 7.4) contained kynuramine (0.3 mM, equivalent to 2×KM) as the substrate 
and purified MAO-A (52 nM). The absorbance change at 30°C was followed at 314 nm in the Uvikon 2101 
spectrophotometer  
The spectrophotometric assay for membrane-bound human MAO-A and MAO-B was measured at 314 
nm and 30°C in a Uvikon 2101 spectrophotometer. In a final volume of 0.4 mL 50 mM potassium phosphate 
pH 7.5, kynuramine was fixed at 2×KM and inhibitor concentration varied over 4 orders of magnitude. 
Membrane-bound MAO-A was used at 1/4000 and MAO-B at 1/2000 of the supplied suspension. The final 
kynuramine concentrations were 60 μM for MAO-A and 30 μM for MAO-B. The linear rates from 8-10 
assays were plotted against the log of inhibitor concentration and analysed using non-linear regression (3-
parameter equation) in GraphPad Prism 4 software with the bottom fixed at zero. The IC50 values are 
shown with the standard error of the parameter estimate. 
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5.2.3. ABAD activity assay 
A modified version of ABAD activity assay has been used to determine inhibitory effect of discussed 
compounds.26 In-house assay reaction conditions consisted of ABAD enzyme (0.5 μg/mL), NADH (250 μM), 
acetoacetyl-CoA (120 μM) and a single compound of interest (100 μM, 1% DMSO (v/v)). Solutions were 
prepared in assay buffer (10 mM HEPES buffer, 0.5% (w/v) gelatin (porcine skin), pH 7.4 at 37°C). Control 
solutions containing an equivalent concentration of DMSO (1% (v/v)) were also prepared and run 
concurrently. Reaction progression was measured via a decrease in NADH absorbance at 340 nm using a 
SpectraMAX M2e spectrophotometer. The reaction period was gated to yield steady state conditions (R2 > 
0.9). Assay validity was demonstrated on compound AG1805143 and experimental data were included in 
Supplementary Information (Fig. S1). 
5.3. Cell viability assessment 
Standard MTT assay (Sigma Aldrich) was used according to the manufacturer’s protocol on the CHO-K1 
cell line (Chinese hamster ovary, ECACC, Salisbury, UK) in order to compare the cytotoxic effect of studied 
compounds. The cells were cultured according to ECACC recommended conditions and seeded in a density 
of 8000 per well as was described earlier.52 Briefly, tested compounds were dissolved in DMSO and 
subsequently in the growth medium (F-12) supplemented with 10% FBS and 1% PEN/STREP so that the final 
concentration of DMSO did not exceed 0.5% (v/v). Cells were exposed to the tested compounds in the 
medium (100 µL) for 24 hours. Then this medium was replaced by the medium containing 10 μM of MTT 
(100 µL) and cells were allowed to produce formazan for another approximately 3 h under surveillance. 
Thereafter, medium with MTT was removed and crystals of formazan were dissolved in DMSO (100 µL). Cell 
viability was assessed spectrophotometrically by the amount of formazan produced. Absorbance was 
measured at 570 nm, with 650 nm as a reference wavelength on Synergy HT reader (BioTek, USA). LC50 was 
then calculated from the control - subtracted triplicates using non-linear regression (four parameters) of 
GraphPad Prism 5 software. Final LC50 and SEM value was obtained as a mean of 3 independent 
measurements. MTT assay was validated with simultaneous tacrine LC50 determination, which is in 
agreement with those reported in literature.49 Triton X (0.1%) has been used as negative control for MTT 
assay, confirming 100% of cells death.  
 
5.4. Prediction of blood-brain barrier permeation 
5.4.1. Chemicals and instrumentation 
In LC-UV-MS analyses, acetonitrile, formic acid, both of LC-MS grade purity (Sigma Aldrich), and 
ultrapure water of ASTM I type (resistance 18.2 MΩ.cm at 25°C) prepared by Barnstead Smart2Pure 3 
UV/UF (ThermoFisher Scientific, Bremen, Germany) apparatus were used for preparation of mobile phases. 
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5.4.2. Parallel artificial membrane permeation assay 
A modification of the parallel artificial membrane permeation assay (PAMPA) has been used based on 
reported protocol.54 The filter membrane of the donor plate was coated with PBL (Polar Brain Lipid, Avanti, 
USA) in dodecane (4 µL of 20 mg/mL PBL in dodecane) and the acceptor well was filled with 300 µL of PBS 
pH 7.4 buffer (VD). Tested compound were dissolved first in DMSO and then diluted with PBS pH 7.4 to 
reach the final concentration 25 µM in the donor well. Concentration of DMSO did not exceed 0.5% (V/V) in 
the donor solution. 300 µL of the donor solution was added to the donor wells (VA) and the donor filter 
plate was carefully put on the acceptor plate so that the coated membrane was “in touch” with both donor 
solution and acceptor buffer. Test compound diffused from the donor well through the lipid membrane 
(Area = 0.28 cm2) to the acceptor well. The concentration of the drug in both donor and the acceptor wells 
was assessed after 3, 4, 5 and 6 hours of incubation in quadruplicate using HPLC. Concentration of the 
compounds was calculated from the standard curve and expressed as the permeability (Pe) according the 
following equation.55,56 
                   
              
                 
            
     
                 
  
 
5.4.3. HPLC analysis 
HPLC analysis of the donor and acceptor solutions from the PAMPA assay was carried out using a 
Dionex UltiMate 3000 analytical system equipped with a Waters Atlantis dC18 (2.1 x 100 mm/3 µm) column 
as the stationary phase. The elution was performed by a linear gradient method utilizing ultra-pure water 
(MPA) and acetonitrile (MPB), both acidified with 0.1% (v) of formic acid. For the elution, following simple 
program was developed: 0-1.0 min 10% MPB, 1.0-4.0 min 10-100% MPB, 4.0-5.0 min 100% MPB, 5.0-
5.0 min 10% MPB, 5.0-7.5 min 10% MPB.52 This 7.5 min long analytical method with mobile phase flow-rate 
set to 0.4 mL/min and injection volume to 5 µL enabled to achieve relatively high sensitivity in UV-detection 
at the wavelength of 278 nm, which was desirable especially for quantification of the analytes in the 
acceptor well. In order to determine the unknown concentrations of the studied compounds in the donor 
and acceptor solutions, an 8-level calibration measurement spanning range of 0.1 – 50 µg/mL was carried 
out. The linearity of calibration for all compounds was confirmed with R2 > 0.999. Processing of UV-
chromatograms and quantification was carried out in Chromeleon 6.80. This HPLC method was also 
employed for uncalibrated purity evaluation (at the wavelength of 254 nm) and for HRMS determination of 
the studied compounds by coupling the analytical system with a Q Exactive Plus mass spectrometer. The 
obtained mass spectra were processed in Xcalibur 3.0.63 software. 
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5.5. Molecular docking 
Structure models of MAO-A (PDB ID: 2Z5X, resolution: 2.2 Å) and MAO-B (PDB ID: 2V5Z, resolution: 
1.6 Å) have been obtained from online PDB database (www.rcsb.org). The protein structure preparation 
process included removal of ligands, residual waters and additive co-crystallized molecules, merging of non-
polar hydrogens, addition of polar hydrogens and assignment of default Gastaiger charges. Further protein 
structure processing for flexible molecular docking was performed with MGL Tools Receptor Python scripts. 
A cavity in 2Z5X was approximated by a docking grid box with 35 Å long edge centered at N5 FAD atom 
(x = 34.176, y = 31.342, z = -14.785).  Analogically, a grid box of the same size was centred at x = 52.895, y 
= 158.664, z = 27.672 within MAO-B 3D model. The ligand 19 was drawn in HyperChem 8.0 and 
geometrically optimized with PM3 semi-empirical method employing Polak-Ribiere conjugate gradient 
algorithm. The structure of ligand was further processed utilizing MGL Tools Ligand Python scripts. 
Molecular docking runs were performed in AutoDock Vina (v1.1.2) using 24 CPUs in parallel with the 
exhaustiveness parameter set to 128.61 Several of the cavity forming residues (MAO-A: Tyr69, Leu97, Gln99, 
Val101, Phe173, Ile180, Asn181, Ile207, Phe208, Ser209, Val210, Gln215, Lys305, Cys323, Met324, Ile325, 
Glu327, Ile335, Thr336, Leu337, Met350, Phe352, Tyr407, Tyr444; MAO-B: Ser59, Tyr60, Gln65, His90, 
Phe99, Phe103, Trp119, Leu164, Leu167, Phe168, Leu171, Cys172, Ile198, Ile199, Ser200, Gln206, Lys296, 
Ile316, Tyr326, Phe343, Tyr398, Tyr435) were assigned as flexible ones. Flexible docking was repeated 10 
times for both enzymes and the top-scored poses were visually inspected with figures generation using 
PyMOL (v1.7). In each docking run, 9 binding modes with the lowest binding energies were stored to 
evaluate all significantly contributing ligand-enzyme interactions. 
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Graphical abstract 
Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s 
disease treatment 
 
 
 
Highlights 
 Novel frentizole-based indolyl thiourea analogues were prepared as potential MAO/ABAD inhibitors. 
 Compound 19 displayed low micromolar and high nanomolar IC50 value for MAO-A and MAO-B 
inhibition. 
 Compounds 17 and 21 showed important structural features for future design of ABAD inhibitors. 
 Several reported compounds acted as low micromolar HRP inhibitors. 
 The active compounds demonstrated low cytotoxicity profile. 
 
 
 
